A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging

A Phase II Open-Label, Non-Randomized, Single-Center Trial to Determine the Optimal Myocardial Perfusion Image Acquisition Time Following BMS068645 Administration

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00162071

Enrollment

Registered

2005-09-13

Start date

2005-07-31

Completion date

Unknown

Last updated

2017-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease, Ischemic Heart Disease

Brief summary

The primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The safety of BMS068645 will also be studied.

Interventions

DRUGapadenoson

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* 18 years of age or older * Have known or suspected heart disease * Have undergone a clinically indicated SPECT MPI study with adenosine in the last 24 hours to 14 days. * Weigh between 88 and 250 lbs.

Exclusion criteria

* Allergic reaction to Technetium Tc99m Sestamibi or any of its components * History of asthma or lung disease * Ingestion of caffeinated substances within 12 hours prior to the study

Design outcomes

Primary

Measure	Time frame
Measurements of Technetium Tc99m Sestamibi activity will be obtained from various regions of the body at the end of the study to determine optimal imaging times.	—

Secondary

Measure	Time frame
A comparison of adverse events will be conducted at the end of the study to assess safety.	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026